Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Status:
Suspended
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well nivolumab with or without varlilumab works in treating
patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond
to treatment (refractory). Immunotherapy with monoclonal antibodies, such as varlilumab and
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Immunoglobulin G Immunoglobulins Nivolumab